Clinical trialPhase 2Withdrawn
Pasireotide in Hyperinsulinemic Hypoglycemia
Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia
- Outcome
- Stopped earlyFunding was withdrawn by Sponsor prior to start of study (Business decision)
- Phase
- Phase 2
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- April 2017
- Planned end
- April 2018
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Hypoglycemia
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 14 May 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.
Detailed description public domain (ClinicalTrials.gov)
Pasireotide is a somatostatin analog with affinity for several somatostatin receptors including those on pancreatic beta cells; when activated these receptors affect the secretion of glucagon and insulin. Pasireotide is also known to decrease glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) secretion. Hyperglycemia is a well-documented adverse effect of pasireotide in its approved indications for treatment of Cushing's disease and acromegaly. In light of this, the investigators hypothesize that pasireotide may be an effective therapy for hypoglycemia due to hyperinsulinism. Therefore a small controlled pilot study to assess the effect of subcutaneous (s.c.) pasireotide on preventing hypoglycemia due to hyperinsulinism over 7 hours of observation in both fasting and fed states is proposed.